NeurologyLive | Direct Access to Expert Insight in Neurology

ATTR Amyloidosis: Updates on the Therapeutic Landscape

With 2 targeted treatments on the market, therapeutic development may now focus on early detection.

Ongoing Unmet Needs for Patients With Epilepsy

A review of the ongoing unmet needs for patients who suffer from seizures that are unable to be controlled from the current armamentarium of medications.

Woven EndoBridge System Proves Positive Option for Wide-Neck Bifurcation Aneurysms

In addition to efficacy end points, the WEB system was markedly safer compared to current treatments, with no primary safety end points occurring between 30 days and 1 year.

Duchenne Muscular Dystrophy Treatment Suvodirsen Safe, Well Tolerated in Phase 1 Trial

The phase 1 results support the initiation of the phase 2/3 clinical trial which is expected to initiate in July 2019.

Zolgensma Effect in SMA Type 1 Echoed in Phase 3 Trial

Data from the STR1VE trial have reinforced the findings from the phase 1 START trial, including inclinations of prolonged survival as well as milestone achievement never seen in the natural history of SMA.

Pascal Sati, PhD: Validating the Central Vein Sign in Multiple Sclerosis Diagnosis

Using Stereo EEG to Evaluate Seizures

Guidelines for Pediatric Migraine Clinical Trial Design Released, FDA Grants AMT-130 Fast Track Designation for Huntington Disease, ZX008 Receives RFL for Dravet Syndrome

Clinical Focus

Video Series

Publications